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ABSTRACT
Objective: This research elucidated the role of silymarin on intestinal alkaline phosphatase (IAP) level in type 2 diabetic rats.
Methods: The type 2 diabetes mellitus was induced by a high-fat diet (HFD - 58% calories fat) for 2 weeks, and rats were intraperitoneally injected 
with streptozotocin (STZ) 35 mg/kg. Wistar rats were divided into four groups. Group I served as a non-diabetic (normal), Group II served as diabetic, 
Group III diabetic animals treated glibenclamide 600 µg/kg for 14 days, and Group IV diabetic animal treated with glibenclamide and silymarin 
50 mg/kg/twice/d for 14 days. At the end of the study, blood glucose, lipid profile, and IAP level were measured.
Results: A significant decrease in IAP, elevated levels of blood glucose, and lipid profile was seen in diabetic rats when compared with normal. The 
silymarin treatment showed a significant increase in IAP level, a significant reduction in glucose and lipid profile than diabetic rats.
Conclusion: The present study concludes that silymarin treatment enhances the IAP levels which protect against hyperglycemia, hyperlipidemia, and 
vascular complications in diabetic rats.
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INTRODUCTION
Diabetes mellitus is a chronic disorder characterized by high blood 
glucose level, insulin resistance, and relative insulin deficiency [1,2]. 
Type 2 diabetes mellitus (T2DM) is more common, because of increases 
in unhealthy food, sedentary lifestyle, and obesity. In later, it developed 
as vascular, neuropathic complications, dysfunction, and failure of 
different organs, especially the kidneys, nerves, heart, and blood 
vessels [3-5]. Diabetic management very challenges to patients and 
health-care systems. Urgently, we require the best choice of treatment 
to reduce the development and progression of diabetes and its 
complications. The high-fat diet (HFD) and streptozotocin (STZ) were 
an ideal model for T2DM because it mimics to metabolic characteristics 
of human T2DM.
Silymarin is flavonolignan, obtained from seeds of Silybum marianum L. 
as medical remedies since the time of ancient Greece. The major 
active constituents are silybin, silychristin, and silydianin, collectively 
called silymarin [6]. It is an antioxidant, hepatoprotective, antidiabetic, 
antihyperlipidemic, anti-inflammatory, antifibrotic, and cytoprotective [7,8]. 
It improves the glycemic control and reduces the diabetic complications. 
Silymarin decreases the triglycerides, very low-density lipoprotein (VLDL) 
synthesis, and the availability of free VLDL secretion in the intestine. It 
reduces lipid accumulation by decreasing adipogenic factors such as fatty 
acid-binding protein 4 and peroxisome proliferator-activated receptor γ [9].
The intestinal microbiota is a pivotal role in maintaining human health 
and well-being. Intestinal alkaline phosphatase (IAP) is an important 
brush border enzyme expressed an entire part of the intestine with the 
highest in the duodenum and produces maximal activity in ileum [10]. 
IAP plays an important role in maintain gut homeostasis. IAP regulates 
intestinal pH, detoxifies bacterial lipopolysaccharide [11] and binds to 
intracellular proteins, and decreases the movement of the fat droplet 
across the enterocyte. The IAP plays a crucial role in decreasing the 
rate of fat absorption. IAP expression is modulated by several nutrition 
substances [12]. IAP is a protective role against hyperlipidemia, T2DM, 
endotoxemia, and metabolic syndrome [13].
Several studies reported the antidiabetic and antihyperlipidemic activity 
of silymarin mainly due to its antioxidant effect and decreased synthesis of 
lipids. IAP supplementation can protect against T2DM. Hence, we evaluate 
the effect of silymarin on IAP levels and their role in T2DM diabetes.
METHODS
Chemicals
Silymarin was obtained from Sigma-Aldrich Chemical Pvt., Limited, 
India. All other drugs and chemicals used in the study were obtained 
commercially and were of analytical grade.
Experimental animals
The Wistar rats (200–250 g) were maintained in clean, sterile, and 
polypropylene cages with paddy husk as bedding. Animals were housed at 
a temperature of 25±2°C and humidity of 30–60%. A 12:12 h light and the 
dark cycle were followed. The animals had free access to food and water 
ad libitum. All the experimental procedures and protocols used in this 
study were reviewed by the institutional animal ethics committee (688/2/
Committee for the Purpose of Control and Supervision of Experiments on 
Animals [CPCSEA]) and were in accordance with the guidelines of the 
IAEC. Animal care was given as per the guidelines of CPCSEA.
Experimental design
The animals are divided into four groups (n=10). Experimental 
diabetes was induced by rats fed with an HFD (58% calories as fat) for 
2 weeks. Then, rats were treated with a single intraperitoneal injection 
of 35 mg/kg of STZ [14]. Rats with marked hyperglycemia fasted blood 
glucose level >200 mg/dL were used for the study.
The animals are divided into four groups (n=10).
• Group I: Normal control (N)
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• Group II: Diabetic rats (HFD+ STZ) (D)
• Group III: Diabetic rats treated with glibenclamide (600 µg/kg) for 
14 days
• Group IV: Diabetic rats +glibenclamide + silymarin 50 mg/kg/twice/d 
for 14 days
Blood samples were collected from the tip of the tail on the 0, 4, 8, 12, 
and 15th day after STZ injection by without sacrificing the animals, from 
the tail vein by snipping off the tip of the tail, and blood glucose was 
checked by glucometer. On the 30th day, animals were anesthetized and 
blood samples were collected by retro-orbital puncture into dry non-
heparinized tubes for serum biochemical profile, and the serum was 
separated by centrifuging at 3000 rpm for 15 min.
Preparation of intestinal homogenate
All rats were sacrificed by cervical dislocation. The intestine was 
removed, flushed with saline, and washed again. The mucosa was 
scraped off with the help of a microscopic glass slide [15]. 10% W/V 
of the mucosa was mixed with 5 mM EDTA (pH - 7.4) and homogenized 
with Teflon pestle. The homogenate was centrifuged and the 
supernatant liquid was used for the estimation of IAP.
Statistical analysis
The data are expressed as the mean ± standard deviation. GraphPad 
Prism software was used to analyze data and construct the graphs. 
One-way analysis of variance followed by Dunnett’s test. The values of 
p<0.05 were regarded as statistically significant.
RESULTS
Effect of silymarin on blood glucose
Blood glucose level of different experimental groups was shown in 
Table 1. The glucose level was significantly (p<0.01) increased in diabetic 
animals compared with normal. The standard drug glibenclamide-
treated animals showed significant (p<0.01) reduction in blood glucose 
level (86 mg/dL) when compared with diabetic control. The silymarin 
and glibenclamide-treated diabetic animals showed 75 mg/dL glucose 
on the 15th day of treatment. Silymarin treatment reduces the blood 
glucose level and used to treat along antidiabetic drugs with caution 
about hypoglycemia or reduces the dose of an antidiabetic drug.
Effect of silymarin on lipid profile
Fig. 1 shows the lipid levels of normal and various experimental 
groups. The diabetic animals showed that cholesterol (168.9 mg/dL), 
triglycerides (190.2 mg/dL), LDL (106.1 mg/dL), and VLDL (38 mg/dL) 
were significantly (p<0.01) increased when compared to the control. 
The positive control animals showed significant  reduction in cholesterol 
(164.1 mg/dL), triglycerides (179.7 mg/dL), LDL (101.3 mg/dL), and 
no significant (p>0.05) difference in VLDL (35.9 mg/dL) and HDL 
(26.9 mg/dL) when compared to diabetic control. The administration 
of silymarin along with glibenclamide showed significant (p<0.01) 
reduction in cholesterol (142.5 mg/dL), triglycerides (121.2 mg/dL), 
LDL (65.2 mg/dL), VLDL (28.5 mg/dL), and increased (p<0.05) HDL 
(27.5 mg/dL) when compared to diabetic control.
Effect of silymarin on IAP levels
The diabetic rats showed the significant (p<0.01) reduction in IAP (2.82 
mU/mg of tissue) levels when compared to control. The antidiabetic 
drug-treated animals showed 2.94 mU of IAP/mg of tissue. Silymarin 
and glibenclamide-treated diabetic rats showed 3.36 mU of IAP/mg of 
tissue. These data suggest that silymarin treatment enhanced the IAP 
concentrations (Table 2).
DISCUSSION
T2DM is a metabolic disorder caused by chronic hyperglycemia, 
primarily occurs in obesity and lack of exercise. The complications of 
T2DM are cardiovascular complications, eye damage, neuropathy, renal 
failure, and infections. The vascular complications of T2DM are due to 
advanced glycated products [16] and primarily by atherosclerosis.
Studies were reported IAP levels that are low in T2DM patients, high 
IAP levels prevent the development of T2DM even though if the person 
is in obese, deficiency of IAP can increase the incidence of T2DM [17]. 
The new therapeutic approach might be involving upregulation of IAP 
by small molecules such as curcumin, omega-3 fatty acid, and corn 
oil [18-20]. Silymarin is an herbal drug with antioxidant and anti-
inflammatory properties; it improves glycemic control and prevents the 
progression of the diabetic complications. The silymarin mechanisms 
of action are not fully understood. Silymarin possesses antioxidant 
activity. It inhibits lipid peroxidation [21,22], prevents glutathione 
depletion [23], and activates antioxidant enzymes that protect DNA 
from degradation [24]. Silymarin administration protects the kidney 
from diabetic damage [25].
In our study showed that silymarin administration decreases the blood 
glucose level in diabetic rats. Our results are consistent with Mohamed 
et al. who reported blood glucose of silymarin-treated group was 
significantly decreased when compared to initial blood glucose [26]. 
Antidiabetic drug glibenclamide coadministered with silymarin 
showed good glycemic control and chances of hypoglycemia. Hence, 
Table 1: Blood glucose levels in different experimental groups
Groups Blood glucose in mg/dL
0th day 4th day 8th day 12th day 15th day
Normal 98±2.6 102±3.2 96±3.6 101±4.1 104±3.5
Diabetic (D) 232±4.8** 243±4.6** 248±2.8** 236±3.7** 231±2.9**
Positive control 228±3.2ns 146±2.8aa 133±4.3aa 98±1.9aa 86±2.2aa
D+glibenclamide+silymarin 236±2.9ns 140±3.6aa 114±2.7aa 88±3.1aa 75±3.4aa
Values are mean±SD; n=10 in each group; **p<0.01 when compared to normal control. nsp>0.05 and aap<0.01 when compared to diabetic control (one-way ANOVA 
followed by Dunnett’s test), SD: Standard deviation
Fig. 1: Lipid profile in different experimental groups. Values 
are mean ± standard deviation; n=10 in each group; **p<0.01 
when compared to normal control. #p<0.05 and ##p<0.01 when 
compared to diabetic control (one-way ANOVA followed by 
Dunnett’s test)
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we need to monitor the blood glucose level and reduce the dose of 
glibenclamide.
Silymarin-treated rats showed decreased total cholesterol, triglyceride, 
VLDL, LDL, and increased HDL levels. Silymarin decreases the VLDL 
synthesis and the availability of free VLDL secretion in the intestine. 
The IAP binds to intracellular proteins and decreases the movement of 
the fat particles across the enterocyte. The IAP decreases fat absorption 
in animals that ingest HFDs [27].
Deficiency of IAP can increase the incidence of T2DM, increase fat 
absorption, increase intestinal inflammation, alter gut integrity, 
and enhance the penetration of microbes [13]. Exogenous 
human recombinant IAP administration protects against this 
hyperlipidemia, diabetes mellitus, and metabolic syndrome and their 
complications [28]. The chronic administration of IAP is required 
to avoid such complications, but the IAP is costly, we searched a 
herbal remedy with low cost and for an alternate for IAP. Silymarin 
was already reported for the treatment of diabetes mellitus and 
hyperlipidemia. However, our study showed that silymarin acts on 
intestine and increases the expression of IAP and protects against 
incidence and progression of T2DM and its complications. In case of 
both Type 1 and T2DM, it may reduce the vascular complications by 
decrease the fat absorption.
CONCLUSION
The present study clearly concluded that the silymarin increased 
the IAP level in the intestine. Silymarin is the cheap herbal remedy 
to prevent incidence and progression of T2DM. Further studies are 
required to analyze the role of silymarin in T1DM complications.
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Table 2: IAP levels in control and experimental groups





Values are mean±SD; n=10 in each group; **p<0.01 when compared to normal 
control. nsp>0.05 and aap<0.01 when compared to diabetic control (one-way 
ANOVA followed by Dunnett’s test), IAP: Intestinal alkaline phosphatase, 
SD: Standard deviation
